European Union-28: An annualised cost-of-illness model for venous thromboembolism

Thrombosis and Haemostasis

Volumn 115, Issue 4, 2016, Pages 800-808

  Barco, Stefano ^a,b   Woersching, Alex L ^c   Spyropoulos, Alex C ^d   Piovella, Franco ^e   Mahan, Charles E ^f  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Annual costs; European Union; Preventable costs; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COST CONTROL; COST OF ILLNESS; COST UTILITY ANALYSIS; DECISION TREE; HEALTH CARE PERSONNEL; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL ADMISSION; HOSPITAL COST; HUMAN; MODEL; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; SENSITIVITY ANALYSIS; VENOUS THROMBOEMBOLISM; ADULT; ECONOMIC MODEL; ECONOMICS; EUROPEAN UNION; HEALTH CARE COST; HOSPITAL; INCIDENCE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; COST OF ILLNESS; EUROPEAN UNION; HEALTH CARE COSTS; HOSPITALS; HUMANS; INCIDENCE; MODELS, ECONOMIC; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84964720696     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-08-0670     Document Type: Article

References (50)

1. ISTH Steering Committee for the World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Thromb Haemost 2014; 112: 843–852.
2. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations – United States, 2007–2009. MMWR Morb Mortal Wkly Rep 2012; 61: 401–404.
3. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011; 86: 217–220.
4. Mahan CE, Borrego ME, Woersching AL, et al. Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 2012; 108: 291–302.
5. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–764.
6. Mahan CE, Holdsworth MT, Welch SM, et al. Deep-vein thrombosis: a United States cost model for a preventable and costly adverse event. Thromb Haemost 2011; 106: 405–415.
7. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692–699.
8. Eurostat Statistics. EU-28 Population 15 and older. Accessed online via http://ec.europa.eu/eurostat/statistics-explained/index.php/File:Population_age_structure_by_major_age_groups,_2002_and_2012_(%25_of_the_total_population)_YB14.png on October 4, 2015.
9. Eurostat Statistics. EU-28 Population. Accessed online via http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_and_population_change_statistics on October 4, 2015.
10. Gomez-Outes A, Rocha E, Martinez-Gonzalez J, et al. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis. Pharmacoeconomics 2006; 24: 81–92.
11. Chanel O, Henschel S, Goodman PG, et al. Economic valuation of the mortality benefits of a regulation on SO2 in 20 European cities. Eur J Public Health 2014; 24: 631–637.
12. Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A costutility analysis. Arch Orthop Trauma Surg 2004; 124: 507–517.
13. Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. Am J Cardiovasc Drugs 2005; 5: 121–130.
14. Goodacre S, Sampson F, Stevenson M, et al. Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis. Health Technol Assess 2006; 10: 1–168, iii-iv.
15. Santamaria A, Juarez S, Reche A, et al. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study. Int J Clin Pract 2006; 60: 518–525.
16. Lundkvist J, Bergqvist D, Jonsson B. Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur J Health Econ 2007; 8: 313–323.
17. McBride D, Brüggenjürgen B, Roll S, et al. Management patterns of thrombosis prophylaxis and related costs in hip and knee replacement in Germany. Open Medicine 2007; 2.
18. Elalamy I, Le Gal G, Nachit-Ouinekh F, et al. Heparin-induced thrombocytopenia: an estimate of the average cost in the hospital setting in France. Clin Appl Thromb Hemost 2009; 15: 428–434.
19. McCullagh L, Tilson L, Walsh C, et al. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics 2009; 27: 829–846.
20. Ten Cate-Hoek AJ, Toll DB, Buller HR, et al. Cost-effectiveness of ruling out deep venous thrombosis in primary care versus care as usual. J Thromb Haemost 2009; 7: 2042–2049.
21. Wilke T, Tesch S, Scholz A, et al. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost 2009; 7: 766–773.
22. Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther 2009; 31: 194–212.
23. Capri S, Ageno W, Imberti D, et al. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis. Intern Emerg Med 2010; 5: 33–40.
24. Norlin JM, Elf JL, Svensson PJ, et al. A cost-effectiveness analysis of diagnostic algorithms of deep vein thrombosis at the emergency department. Thromb Res 2010; 126: 195–199.
25. Wilkens H, Grimminger F, Hoeper M, et al. Burden of pulmonary arterial hypertension in Germany. Respir Med 2010; 104: 902–910.
26. Lecumberri R, Panizo E, Gomez-Guiu A, et al. Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. J Thromb Haemost 2011; 9: 1108–1115.
27. Kroger K, Kupper-Nybelen J, Moerchel C, et al. Prevalence and economic burden of pulmonary embolism in Germany. Vasc Med 2012; 17: 303–309.
28. Migliaccio-Walle K, Rublee D, Simon TA. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. Postgrad Med 2012; 124: 41–49.
29. Postma MJ, Kappelhoff BS, van Hulst M, et al. Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. J Med Econ 2012; 15: 878–886.
30. Italian Ministry of Health. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Gazzetta Ufficiale 2012; 23.
31. Zindel S, Stock S, Muller D, et al. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res 2012; 12: 192.
32. Gussoni G, Foglia E, Frasson S, et al. Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res 2013; 131: 17–23.
33. Monreal M, Folkerts K, Diamantopoulos A, et al. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thromb Haemost 2013; 110: 987–994.
34. Santos IF, Pereira S, McLeod E, et al. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal. Acta Med Port 2014; 27: 615–624.
35. Department of Health (UK). NHS reference costs 2013 to 2014. Accessed online via https://www.gov.uk/government/publications/nhs-reference-costs2013-to-2014 on October 4, 2015.
36. Relman A. A Second Opinion: Rescuing America’s Health Care (A Century Foundation Book). New York, Public Affairs, 2007. p. 205.
37. Caraballo D, Spyropoulos AC, Mahan CE. Identifying, monitoring and reducing preventable major bleeds in the hospital setting. J Thromb Thrombolysis 2013; 36: 7–13.
38. US Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention 2014. Accessed online via http: //health.gov/hcq/pdfs/ADE-ActionPlan-508c.pdf on October 10, 2015.
39. Portola. Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) 2012. Accessed online via https://clinicaltrials.gov/ct2/show/NCT01583218 on October 4, 2015.
40. Janssen. A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER) 2014. Accessed online via https://clinicaltrials.gov/ct2/show/NCT02111564?term=mariner&rank=1 on October 04, 2015.
41. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e227S-77S.
42. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e195S-226S.
43. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7: 322–337.
44. Gibson GJ LR, Sibille Y, Lundbäck B. The European Lung White Book. Sheffield, European Respiratory Society. European Respiratory Society 2013.
45. Nichols M TN, Luengo-Fernandez R, Leal J, et al. European cardiovascular disease statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis 2012.
46. Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst 2008; 100: 1763–1770.
47. van Leent MW, Stevanovic J, Jansman FG, et al. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data. PLoS One 2015; 10: e0135054.
48. Lankeit M, Konstantinides S. Is it time for home treatment of pulmonary embolism? Eur Respir J 2012; 40: 742–749.
49. Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014; 17: 52–64.
50. Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J 2015; 13: 20.